Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. News
  7. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

06/24/2021 | 11:45am EDT

Transgene announced that a first patient has been enrolled in a randomized, controlled Phase II study evaluating the combination of TG4001 with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors. TG4001 IS AN INVESTIGATIONAL THERAPEUTIC VACCINE TARGETING HPV-POSITIVE TUMORS, including cervical, anal, and other anogenital cancers. It is based on a Vaccinia vector, which is engineered to express HPV16 E6 and E7 antigens and interleukin 2 (IL-2). TG4001 is designed to alert the immune system specifically to cells presenting these HPV antigens and to induce a specific cellular immune response against these cancer cells. Based on promising data obtained in the Phase Ib/II part of the trial, Transgene is progressing the development of TG4001 in combination with avelumab, through a randomized Phase II trial and an extended collaboration with the alliance of Merck KGaA, Darmstadt, Germany, and Pfizer, which is supplying avelumab. The randomized Phase II trial is focusing on patients with recurrent or metastatic HPV16-positive anogenital cancer, including cervical, vulvar, vaginal, penile, and anal cancer, without liver metastases. In the Phase Ib/II part of the study, very encouraging clinical outcome was observed in patients without liver metastases. Patients will be randomized to either receive the combination regimen of the therapeutic vaccine TG4001 and avelumab or avelumab alone. The trial will be enrolling patients in the USA and in Europe. The primary endpoint of the trial is progression-free survival according to RECIST 1.1. Secondary endpoints include objective response rate, disease control rate, overall survival and a series of immunological parameters.


© S&P Capital IQ 2021
All news about TRANSGENE
10/01BIOINVENT INTERNATIONAL : and Transgene to present preclinical data on BT-001 oncolytic vi..
AQ
10/01Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2..
CI
09/23Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 23..
CI
09/16TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing Virus
MT
09/16Transgene Presents Data from Phase I Clinical Trial Confirming the Potential of the Onc..
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/07PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufa..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01Transgene Participates in New Cancer Research Consortium
CI
06/28Transgene Announces Update on Phase I Clinical Trial of TG4050
CI
More news
Financials
Sales 2021 11,1 M 12,9 M 12,9 M
Net income 2021 -27,0 M -31,4 M -31,4 M
Net cash 2021 44,7 M 52,0 M 52,0 M
P/E ratio 2021 -8,57x
Yield 2021 -
Capitalization 234 M 272 M 273 M
EV / Sales 2021 17,1x
EV / Sales 2022 27,3x
Nbr of Employees 133
Free-Float 44,0%
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,40 €
Average target price 3,80 €
Spread / Average Target 58,3%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE45.63%272
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%66 875
BIONTECH SE222.44%63 484
REGENERON PHARMACEUTICALS14.28%57 402
VERTEX PHARMACEUTICALS-21.55%48 101